• Syndax Pharmaceuticals’ Head of R&D and CMO Nicholas A.J. Botwood sold 65,515 shares on June 11-12 at weighted-average prices of $18 and $18.14.
• Sales followed option exercises totaling 53,750 shares at $13.82.
• Botwood’s direct holding ended at 60,885 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-269694), on June 12, 2026, and is solely responsible for the information contained therein.